| Drug Name |
Adefovir dipivoxil |
| Drug ID |
BADD_D00044 |
| Description |
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir. |
| Indications and Usage |
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AF08 |
| DrugBank ID |
DB00718
|
| KEGG ID |
D01655
|
| MeSH ID |
C106812
|
| PubChem ID |
60871
|
| TTD Drug ID |
D0ML1F
|
| NDC Product Code |
53104-7602; 42794-003; 60505-3947; 61958-0501 |
| UNII |
U6Q8Z01514
|
| Synonyms |
adefovir dipivoxil | adefovir depivoxil | 9-(2-((-bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine | Hepsera | Preveon | GS 840 | GS-0840 |
